Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 48.4% in October

Bone Biologics Co. (NASDAQ:BBLG) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 72,100 shares, an increase of 48.4% from the October 15th total of 48,600 shares. Currently, 13.8% of the company’s stock are short sold. Based on an average daily volume of 3,010,000 shares, the days-to-cover ratio is currently 0.0 days.

Bone Biologics Stock Performance

Shares of NASDAQ:BBLG traded down $0.10 during mid-day trading on Friday, hitting $1.19. 128,261 shares of the company traded hands, compared to its average volume of 1,525,457. Bone Biologics has a 52-week low of $0.80 and a 52-week high of $10.56. The firm’s 50 day simple moving average is $1.64 and its 200 day simple moving average is $1.59.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.